World's Best Scientists 2026 revealed!
John H. Sampson

John H. Sampson

D-Index & Metrics

Medicine

D-Index
111
Citations
41987
World Ranking
5362
National Ranking
2891

John H. Sampson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John H. Sampson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 645 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John H. Sampson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John H. Sampson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 111 D-Index — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2017 - Member of the National Academy of Medicine (NAM)
  • 1951 - Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

John H. Sampson is affiliated with Duke University in the United States and has an extensive research portfolio primarily in medicine and immunology and microbiology. Their work spans various subfields including immunology, oncology, genetics, molecular biology, and biotechnology.

Their main areas of research focus on topics such as:

  • Glioma Diagnosis and Treatment
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Cancer Immunotherapy and Biomarkers
  • Cancer Research and Treatments
  • Immune cells in cancer
  • RNA Interference and Gene Delivery

They have contributed to several frequently published venues, including:

  • Neuro-Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Neuro-Oncology Advances
  • Cancer Research

Selected recent papers authored or co-authored by John H. Sampson include:

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020, JAMA Oncology)
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial (2020, Clinical Cancer Research)
  • Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement (2021, Clinical Cancer Research)
  • PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? (2020, Clinical Cancer Research)
  • Current multidisciplinary management of brain metastases (2020, Cancer)

Frequent collaborators in their research include:

  • Mustafa Khasraw
  • Kelly Hotchkiss
  • David M. Ashley
  • James E. Herndon
  • Annick Desjardins

John H. Sampson has been recognized by professional organizations with memberships and fellowships, including:

  • Member of the National Academy of Medicine (NAM) since 2017
  • Fellow of the American Association for the Advancement of Science (AAAS)
  • Member of the Association of American Physicians

Best Publications

  • Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

    James J. Vredenburgh;Annick Desjardins;James E. Herndon;Jennifer Marcello

  • Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

    David A. Reardon;Alba A. Brandes;Antonio Omuro;Paul Mulholland

  • Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

    John H. Sampson;Amy B Heimberger;Gary E. Archer;Kenneth D. Aldape

  • Phase II Trial of Gefitinib in Recurrent Glioblastoma

    Jeremy N. Rich;David A. Reardon;Terry Peery;Jeannette M. Dowell

  • Recurrent glioblastoma treated with recombinant poliovirus

    Annick Desjardins;Matthias Gromeier;James E. Herndon;Nike Beaubier

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • Challenges to curing primary brain tumours

    Kenneth Aldape;Kevin M Brindle;Louis Chesler;Rajesh Chopra

  • Brain immunology and immunotherapy in brain tumours

    John H. Sampson;Michael D. Gunn;Peter E. Fecci;David M. Ashley

  • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

    Peter E. Fecci;Duane A. Mitchell;John F. Whitesides;Weihua Xie

  • Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma

    John H. Sampson;James H. Carter;Allan H. Friedman;Hilliard F. Seigler

  • Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

    Pakawat Chongsathidkiet;Christina Jackson;Shohei Koyama;Franziska Loebel

  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

    Duane A. Mitchell;Kristen A. Batich;Michael D. Gunn;Min-Nung Huang

  • Proteomic and immunologic analyses of brain tumor exosomes

    Michael W. Graner;Oscar Alzate;Angelika M. Dechkovskaia;Jack D. Keene

  • Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

    Sandeep Kunwar;Susan Chang;Manfred Westphal;Michael Vogelbaum

  • Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

    Antonio Omuro;Gordana Vlahovic;Michael Lim;Solmaz Sahebjam

  • Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma

    Duane A. Mitchell;Weihua Xie;Robert Schmittling;Chris Learn

  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    James Schuster;Rose K. Lai;Rose K. Lai;Lawrence D. Recht;David A. Reardon;David A. Reardon

  • Prospects of immune checkpoint modulators in the treatment of glioblastoma.

    Matthias Preusser;Michael Lim;David A. Hafler;David A. Reardon

  • OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

    D. A. Reardon;A. Omuro;A. A. Brandes;J. Rieger;J. Rieger

  • Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

    David A. Reardon;Gamal Akabani;R. Edward Coleman;Allan H. Friedman

Frequent Co-Authors

Darell D. Bigner
Darell D. Bigner Duke University
James E. Herndon
James E. Herndon Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Henry S. Friedman
Henry S. Friedman Duke University
David A. Reardon
David A. Reardon Harvard University
Gary E. Archer
Gary E. Archer Duke University
Roger E. McLendon
Roger E. McLendon Duke University
James J. Vredenburgh
James J. Vredenburgh Yale School of Medicine
Jeremy N. Rich
Jeremy N. Rich University of Pittsburgh
Smita Nair
Smita Nair Duke University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Expanding your medical education beyond a traditional MD program can open new doors in healthcare. Many students are now exploring 1 year dnp program online options to quickly advance in nursing leadership roles. These programs offer greater flexibility for working professionals.

If you’re interested in the pharmaceutical field, online pharmd programs provide a pathway to becoming a pharmacist without sacrificing your current commitments. These accredited degrees allow you to balance work and study, making it easier to upskill or change careers.

For high school students interested in healthcare, the best online schools for high school students can provide early access to courses in medicine, health management, and science, which helps build a strong foundation before entering college-level programs.

Those considering administrative roles may also ask, how much does it cost to become a medical coder? Fortunately, affordable online medical billing and coding courses make this career accessible and cost-effective for many, with the added benefit of being able to study at your own pace.

Best Scientists Citing John H. Sampson

Trending Scientists

Recently Published Articles